Transmedics (TMDX) Stock
Leading organ preservation systems for transplant hospitals. Here's the price, business snapshot, and what's worth knowing about Transmedics in October 2026.
TransMedics Group Inc (TMDX) develops organ preservation and transport systems designed to improve transplant outcomes and expand donor organ utilisation. Its flagship Organ Care System (OCS) platforms keep hearts, lungs and livers functioning outside the body by perfusing them with warm, oxygenated blood, enabling longer preservation, active assessment and potential use of marginal donors. The company generates revenue from capital equipment sales and recurring disposables used for each transplant, supported by training and clinical data to drive adoption. Growth depends on clinical acceptance, reimbursement, regulatory approvals and transplant volumes; the business can offer attractive recurring revenue if hospitals scale use. Key risks include regulatory or clinical setbacks, reimbursement uncertainty, hospital purchasing cycles, competition and historical operating losses. Market cap is approximately US$4.1bn (provided). This is general educational information, not personal financial advice; values can fall as well as rise.
Transmedics (TMDX) Stock Forecast
Analyst price target, next 12 months
$107.61
+52.1% vs today's $70.74
Price range over the last 12 months
Close to its 12-month low
Analysts covering Transmedics have a consensus 12-month target of $107.61, above the current price of $70.74.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying TransMedics stock, predicting it could rise significantly in value.
Financial Health
TransMedics Group is performing well with strong revenue, cash flow, and profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring Consumables Demand
Each transplant uses single‑use disposables, offering recurring revenue potential as procedures scale, though volumes rely on adoption and reimbursement.
Clinical Outcomes Focus
OCS lets clinicians assess organs outside the body, which may increase usable donors; clinical evidence and trial results will influence uptake.
Addressing Organ Shortage
The global transplant market is substantial and the technology targets unmet need, but growth depends on hospital budgets, regulation and payer support.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
